EUVIMEDDescoperă EUVIMED
Open access · CC BY 4.0

Loss of ESRP2 Activates TAK1‐MAPK Signaling through the Fetal RNA‐Splicing Program to Promote Hepatocellular Carcinoma Progression

Qian Yan iD, Xiaona Fang, Xiaoxia Liu, Sai Guo, Siqi Chen, Min Luo, Ping Lan iD, Xin-Yuan Guan iD

Advanced Science · 2024-01 · 11 (1)

DOI: 10.1002/advs.202305653 ↗

At a glance

Journal article in Advanced Science, published online on 2023-11-20. Written by Qian Yan and 7 co-authors. Institution: Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, …. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms. Cited 17 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Science and Technology Program.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Tumors usually display fetal‐like characteristics, and many oncofetal proteins have been identified. However, fetal‐like reprogramming of RNA splicing in hepatocellular carcinoma (HCC) is poorly understood. Here, it is demonstrated that the expression of epithelial splicing regulatory protein 2 (ESRP2), an RNA splicing factor, is suppressed in fetal hepatocytes and HCC, in parallel with tumor progression. By combining RNA‐Seq with splicing analysis, it is identified that ESRP2 controls the fetal‐to‐adult switch of multiple splice isoforms in HCC. Functionally, ESRP2 suppressed cell proliferation and migration by specifically switching the alternative splicing (AS) of the TAK1 gene and restraining the expression of the fetal and oncogenic isoform, TAK1_ΔE12. Notably, aberrant TAK1 splicing led to the activation of p38MAPK signaling and predicted poor prognosis in HCC patients. Further investigation revealed that TAK1_ΔE12 protein interacted closely with TAB3 and formed liquid condensation in HCC cells, resulting in p38MAPK activation, enhanced cell migration, and accelerated tumorigenesis. Loss of ESRP2 sensitized HCC cells to TAK1 kinase inhibitor (TAK1i), promoting pyroptotic cell death and CD8+ T cell infiltration. Combining TAK1i with immune checkpoint therapy achieved potent tumor regression in mice. Overall, the findings reveal a previously unexplored onco‐fetal reprogramming of RNA splicing and provide novel therapeutic avenues for HCC.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansMiceAnimalsHepatocytesAlternative SplicingProtein IsoformsRNARNA-Binding Proteins

Author keywords

RNA splicingTAK1/MAPK activationepithelial splicing regulatory protein 2fetal reprogramminghepatocellular carcinoma

Substances

Protein IsoformsRNAESRP2 protein, humanRNA-Binding Proteins

Authors and institutions

  • Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
  • Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
  • Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
  • Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
  • Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
  • Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.

ORCID profiles: Qian Yan, Ping Lan, Xin-Yuan Guan

Funding

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangzhou Science and Technology Program
  • National Key R&D Program of China
  • National Key Clinical Discipline, Shenzhen Fundamental Research Program
  • Shenzhen Science and Technology Program
  • Hong Kong Research Grant Council grants including GRF
  • Collaborative Research Funds

Cite

APA

Yan, Q., Fang, X., Liu, X., Guo, S., Chen, S., Luo, M., Lan, P., & Guan, X. Y. (2024). Loss of ESRP2 Activates TAK1‐MAPK Signaling through the Fetal RNA‐Splicing Program to Promote Hepatocellular Carcinoma Progression. Advanced Science, 11(1). https://doi.org/10.1002/advs.202305653

Vancouver

Yan Q, Fang X, Liu X, Guo S, Chen S, Luo M, et al. Loss of ESRP2 Activates TAK1‐MAPK Signaling through the Fetal RNA‐Splicing Program to Promote Hepatocellular Carcinoma Progression. Advanced Science. 2024;11(1). doi:10.1002/advs.202305653

BibTeX
@article{Yan2024,
  author = {Yan, Qian and Fang, Xiaona and Liu, Xiaoxia and Guo, Sai and Chen, Siqi and Luo, Min and Lan, Ping and Guan, Xin-Yuan},
  title = {Loss of ESRP2 Activates TAK1‐MAPK Signaling through the Fetal RNA‐Splicing Program to Promote Hepatocellular Carcinoma Progression},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {1},
  doi = {10.1002/advs.202305653}
}
Start for free →